Protocol Ledger

NCT03692312 · Phase II/III · COMPLETED

Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy

Interventional Phase II/III clinical trial protocol NCT03692312 sponsored by AMO Pharma Limited in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-03-03 Enrollment: 56 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03692312
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)56 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03692312
Protocol FieldVerified Registry Value
NCT IdentifierNCT03692312
Consolidated Lead SponsorAMO Pharma Limited
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusCOMPLETED
Registered Enrollment56 participants (ACTUAL)
Registered Start Date2021-03-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI